Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
19.89
+0.64 (3.32%)
Feb 21, 2025, 4:00 PM EST - Market closed
Cadrenal Therapeutics Employees
Cadrenal Therapeutics had 4 employees as of December 31, 2023. The number of employees increased by 1 or 33.33% compared to the previous year.
Employees
4
Change (1Y)
1
Growth (1Y)
33.33%
Revenue / Employee
n/a
Profits / Employee
-$1,902,040
Market Cap
35.45M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 4 | 1 | 33.33% |
| Dec 31, 2022 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
CVKD News
- 16 days ago - Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin - Business Wire
- 17 days ago - Cadrenal Therapeutics to Present at BIO CEO & Investor Conference - Business Wire
- 6 weeks ago - Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - Business Wire
- 7 weeks ago - Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications - Business Wire
- 2 months ago - Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings - Business Wire
- 3 months ago - Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook - PRNewsWire
- 3 months ago - CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS - PRNewsWire
- 3 months ago - CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE - PRNewsWire